Lilly adds gene delivery technology to CAR T in up to $7B Kelonia deal

After entering the CAR T space in February, Eli Lilly is “jumping into in vivo CAR-T with both feet” with the acquisition of Kelonia Therapeutics and its gene delivery technology.